The Clinical Research Office at PHSU. Innovating Research and Clinical Trials in Puerto Rico. Learn about our capabilities, Moffitt Cancer Center Collaboration, and the Puerto Rico Clinical Trials Network.
Outlining the proces and lessons learned in organising the technological infrastructure at the Radboud university medical center, to shape the Radboudumc Technology Centers, supporting our mission in enabling personalized healthcare.
Is your clinical trial in jeopardy? KCR's comprehensive rescue support will expeditiously steer it back on track. Taking over each rescue study on a case-by-case basis, our team of experts quickly analyze its status and provide accurate solutions to bring it back on track in a timely manner maintaining its safety,efficacy, and validity.
The Medical Affairs team at GVK Biosciences (GVK BIO) comprises of well trained medical professionals with cumulative Clinical Research experience of about 28 years.
This is the presentation of our facilities as well as therapeutic areas we are able to manage. 14 years ofcumulated experience in Clinical Research field in Mexico and Latin America make us your best choice in Clinical Research centres in Mexico.
The Business of Genomic Testing by James CrawfordKnome_Inc
View this webinar at: http://www.knome.com/webinar-business-of-genomic-testing. This presentation discusses the findings of a College of American Pathologists survey of “early adopters” of NGS recently published in "Genetics in Medicine". The study objective was to identify the reasons for health systems to bring next-generation sequencing into their clinical laboratories and to understand the process by which such decisions were made. A standardized open-ended interview was conducted with the laboratory medical directors and/or department of pathology chairs of 13 different academic institutions in 10 different states.
Dr. Sarah Tomlinson - Diagnostic Technology Update: Strategic Development and...John Blue
Diagnostic Technology Update: Strategic Development and Deployment - Dr. Sarah Tomlinson, Associate NAHLN Coordinator at USDA-APHIS-VS, from the 2013 NIAA Merging Values and Technology conference, April 15-17, 2013, Louisville, KY, USA.
More presentations at http://www.trufflemedia.com/agmedia/conference/2013-niaa-merging-values-and-technology
CHI’s Thirteenth Annual High-Content Analysis meeting, the premier event showcasing the latest advancements in HCA applications and technologies, returns to San Diego with a new program. Over the years we have observed the technology mature and its adoption spread into many areas of compound screening/evaluation and functional analysis. The High-Content Analysis meeting will focus on the next steps of technology development, including screening of 3D and physiologically relevant complex models, ultra-high resolution and high-throughput imaging, more advanced image analysis and data management, and new assays and applications. The co-located Second Annual Phenotypic Screening meeting will address the advantages of phenotypic screening vs. target-based screening, and focus on assay development, selection of physiologically relevant models and subsequent target identification, as well as case studies of phenotypic screens from leading pharma. Join the original High-Content Analysis event and get access to two tracks featuring a cutting-edge scientific agenda, expanded exhibit hall and technology showcases, and an offering of technology demonstrations and dinner courses.
According to a 2016 Nature survey, more than 70% of researchers have failed to reproduce another scientist’s experiments. To solve the reproducibility problem, the research community demands high-quality biobanks to deliver fit-for-purpose biospecimens – key pillars advancing science in medicine. Precision for Medicine is a global leader in supplying diverse, high quality, IRB-approved, clinically annotated, ready-to-ship human biospecimens.
This talk provides an insider’s look into Precision for Medicine’s variant-rich biobank showcasing biospecimen types, highlighting usage, custom collection solutions and disease-matched control sets across multiple therapeutic areas. Precision for Medicine’s biorepository contains diverse, genetically characterized specimens validated using various NGS assays and platforms.
Described in this talk are just some of the sample types, screening methods, and subsequently the integrated QuartzBio database of variants found. The speakers also discuss Precision for Medicine’s partnership capabilities, such as for supporting companion diagnostic development including inter-laboratory reproducibility, validation kit assembly and prospective collections for matched tissue types, minimal residual disease, and clinical trial enrollment.
Key Topics Include:
- Gain a broad understanding of Precision for Medicine, Biospecimen Solutions variant-rich biobank contents pertaining to different therapeutic areas
- Become familiar with fit-for-purpose human biospecimens, their diverse types and appropriate uses
- Become acquainted with the biospecimen characterization data available from Precision for
Medicine, Biospecimen Solutions
- Discover the various partnership options for sample and patient screening for R&D and CDx development and clinical trial enrollment
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
An overview of the oncology clinical trials network (CTNeT) which is being implemented throughout Texas.
The non-profit network is a first of its kind and combines the innovative science of Texas cancer centers with the expertise and resources of both academic and community oncologists throughout the state.
To learn more, visit www.ctnet.org
Presentation on theme: "GCP (GOOD CLINICAL PRACTISE)"Nevin Francis
Creating a comprehensive 3000-word essay on Good Clinical Practice (GCP) would be quite extensive and may not fit within the scope of our conversation here. However, I can provide you with a detailed outline and key points that you could expand upon to reach the desired word count.
**Introduction to Good Clinical Practice (GCP)**
- Definition and importance of GCP in clinical research.
- Historical development and international harmonization efforts.
**Ethical Considerations in GCP**
- The role of ethics in clinical trials.
- Informed consent process and protection of participants' rights.
**Designing Clinical Trials under GCP Guidelines**
- Key elements in the design of a clinical trial.
- Considerations for protocol development.
**Conducting Clinical Trials According to GCP**
- Responsibilities of sponsors and investigators.
- Patient recruitment and data management strategies.
**Safety Monitoring and Adverse Event Reporting**
- Monitoring patient safety and reporting adverse events.
- The role of Data Safety Monitoring Boards (DSMBs).
**Quality Assurance in Clinical Trials**
- Audits, inspections, and ensuring compliance with GCP.
- The significance of documentation and record-keeping.
**Statistical Considerations in Clinical Trials**
- Importance of statistical methods in trial design and analysis.
- Interpreting results and determining clinical significance.
**The Future of GCP and Clinical Research**
- Innovations in clinical trial methodology.
- The impact of technology on GCP and patient engagement.
**Conclusion**
- The ongoing importance of GCP for the integrity of clinical research.
- The global impact of GCP on healthcare and medicine.
Each of these sections can be elaborated to create a full essay that discusses the principles and practices of GCP in depth. For the most current and detailed information, you can refer to the ICH E6 (R2) Good Clinical Practice guidelines¹, which are recognized internationally and provide a comprehensive framework for conducting clinical trials that involve human subjects. Additionally, the draft version of the ICH E6 (R3) principles provides updated guidance on ethical trial conduct, participant safety, and reliable results².
Remember, while expanding on these points, it's essential to cite relevant guidelines, regulations, and literature to support your discussion and provide a well-rounded view of GCP.
Source: Conversation with Bing, 19/02/2024
(1) ICH E6 (R2) Good clinical practice - Scientific guideline. https://www.ema.europa.eu/en/ich-e6-r2-good-clinical-practice-scientific-guideline.
(2) ICH-E6 Good Clinical Practice (GCP). https://database.ich.org/sites/default/files/ICH_E6-R3_GCP-Principles_Draft_2021_0419.pdf.
(3) ICH Guidance Documents | FDA. https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/ich-guidance-documents.
(4) Good Clinical Practice Guidelines (India) - Rajiv Gandhi Centre for .... https://www.rgcb.res.in/documents/Good-Clinical-Practice-Gu
Outlining the proces and lessons learned in organising the technological infrastructure at the Radboud university medical center, to shape the Radboudumc Technology Centers, supporting our mission in enabling personalized healthcare.
Is your clinical trial in jeopardy? KCR's comprehensive rescue support will expeditiously steer it back on track. Taking over each rescue study on a case-by-case basis, our team of experts quickly analyze its status and provide accurate solutions to bring it back on track in a timely manner maintaining its safety,efficacy, and validity.
The Medical Affairs team at GVK Biosciences (GVK BIO) comprises of well trained medical professionals with cumulative Clinical Research experience of about 28 years.
This is the presentation of our facilities as well as therapeutic areas we are able to manage. 14 years ofcumulated experience in Clinical Research field in Mexico and Latin America make us your best choice in Clinical Research centres in Mexico.
The Business of Genomic Testing by James CrawfordKnome_Inc
View this webinar at: http://www.knome.com/webinar-business-of-genomic-testing. This presentation discusses the findings of a College of American Pathologists survey of “early adopters” of NGS recently published in "Genetics in Medicine". The study objective was to identify the reasons for health systems to bring next-generation sequencing into their clinical laboratories and to understand the process by which such decisions were made. A standardized open-ended interview was conducted with the laboratory medical directors and/or department of pathology chairs of 13 different academic institutions in 10 different states.
Dr. Sarah Tomlinson - Diagnostic Technology Update: Strategic Development and...John Blue
Diagnostic Technology Update: Strategic Development and Deployment - Dr. Sarah Tomlinson, Associate NAHLN Coordinator at USDA-APHIS-VS, from the 2013 NIAA Merging Values and Technology conference, April 15-17, 2013, Louisville, KY, USA.
More presentations at http://www.trufflemedia.com/agmedia/conference/2013-niaa-merging-values-and-technology
CHI’s Thirteenth Annual High-Content Analysis meeting, the premier event showcasing the latest advancements in HCA applications and technologies, returns to San Diego with a new program. Over the years we have observed the technology mature and its adoption spread into many areas of compound screening/evaluation and functional analysis. The High-Content Analysis meeting will focus on the next steps of technology development, including screening of 3D and physiologically relevant complex models, ultra-high resolution and high-throughput imaging, more advanced image analysis and data management, and new assays and applications. The co-located Second Annual Phenotypic Screening meeting will address the advantages of phenotypic screening vs. target-based screening, and focus on assay development, selection of physiologically relevant models and subsequent target identification, as well as case studies of phenotypic screens from leading pharma. Join the original High-Content Analysis event and get access to two tracks featuring a cutting-edge scientific agenda, expanded exhibit hall and technology showcases, and an offering of technology demonstrations and dinner courses.
According to a 2016 Nature survey, more than 70% of researchers have failed to reproduce another scientist’s experiments. To solve the reproducibility problem, the research community demands high-quality biobanks to deliver fit-for-purpose biospecimens – key pillars advancing science in medicine. Precision for Medicine is a global leader in supplying diverse, high quality, IRB-approved, clinically annotated, ready-to-ship human biospecimens.
This talk provides an insider’s look into Precision for Medicine’s variant-rich biobank showcasing biospecimen types, highlighting usage, custom collection solutions and disease-matched control sets across multiple therapeutic areas. Precision for Medicine’s biorepository contains diverse, genetically characterized specimens validated using various NGS assays and platforms.
Described in this talk are just some of the sample types, screening methods, and subsequently the integrated QuartzBio database of variants found. The speakers also discuss Precision for Medicine’s partnership capabilities, such as for supporting companion diagnostic development including inter-laboratory reproducibility, validation kit assembly and prospective collections for matched tissue types, minimal residual disease, and clinical trial enrollment.
Key Topics Include:
- Gain a broad understanding of Precision for Medicine, Biospecimen Solutions variant-rich biobank contents pertaining to different therapeutic areas
- Become familiar with fit-for-purpose human biospecimens, their diverse types and appropriate uses
- Become acquainted with the biospecimen characterization data available from Precision for
Medicine, Biospecimen Solutions
- Discover the various partnership options for sample and patient screening for R&D and CDx development and clinical trial enrollment
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
An overview of the oncology clinical trials network (CTNeT) which is being implemented throughout Texas.
The non-profit network is a first of its kind and combines the innovative science of Texas cancer centers with the expertise and resources of both academic and community oncologists throughout the state.
To learn more, visit www.ctnet.org
Presentation on theme: "GCP (GOOD CLINICAL PRACTISE)"Nevin Francis
Creating a comprehensive 3000-word essay on Good Clinical Practice (GCP) would be quite extensive and may not fit within the scope of our conversation here. However, I can provide you with a detailed outline and key points that you could expand upon to reach the desired word count.
**Introduction to Good Clinical Practice (GCP)**
- Definition and importance of GCP in clinical research.
- Historical development and international harmonization efforts.
**Ethical Considerations in GCP**
- The role of ethics in clinical trials.
- Informed consent process and protection of participants' rights.
**Designing Clinical Trials under GCP Guidelines**
- Key elements in the design of a clinical trial.
- Considerations for protocol development.
**Conducting Clinical Trials According to GCP**
- Responsibilities of sponsors and investigators.
- Patient recruitment and data management strategies.
**Safety Monitoring and Adverse Event Reporting**
- Monitoring patient safety and reporting adverse events.
- The role of Data Safety Monitoring Boards (DSMBs).
**Quality Assurance in Clinical Trials**
- Audits, inspections, and ensuring compliance with GCP.
- The significance of documentation and record-keeping.
**Statistical Considerations in Clinical Trials**
- Importance of statistical methods in trial design and analysis.
- Interpreting results and determining clinical significance.
**The Future of GCP and Clinical Research**
- Innovations in clinical trial methodology.
- The impact of technology on GCP and patient engagement.
**Conclusion**
- The ongoing importance of GCP for the integrity of clinical research.
- The global impact of GCP on healthcare and medicine.
Each of these sections can be elaborated to create a full essay that discusses the principles and practices of GCP in depth. For the most current and detailed information, you can refer to the ICH E6 (R2) Good Clinical Practice guidelines¹, which are recognized internationally and provide a comprehensive framework for conducting clinical trials that involve human subjects. Additionally, the draft version of the ICH E6 (R3) principles provides updated guidance on ethical trial conduct, participant safety, and reliable results².
Remember, while expanding on these points, it's essential to cite relevant guidelines, regulations, and literature to support your discussion and provide a well-rounded view of GCP.
Source: Conversation with Bing, 19/02/2024
(1) ICH E6 (R2) Good clinical practice - Scientific guideline. https://www.ema.europa.eu/en/ich-e6-r2-good-clinical-practice-scientific-guideline.
(2) ICH-E6 Good Clinical Practice (GCP). https://database.ich.org/sites/default/files/ICH_E6-R3_GCP-Principles_Draft_2021_0419.pdf.
(3) ICH Guidance Documents | FDA. https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/ich-guidance-documents.
(4) Good Clinical Practice Guidelines (India) - Rajiv Gandhi Centre for .... https://www.rgcb.res.in/documents/Good-Clinical-Practice-Gu
Accelerating the translation of medical research - 27 JuneInnovation Agency
Slides from the event focusing on translational research in Liverpool and North of England and why companies are establishing and growing operations in the region.
Aldo Rolfo, National Clinical Development Manager, Genesis Cancer Care, Austr...GenesisCareUK
A program that seeks to redefine best practice across the drivers of the GenesisCare business (Quality, Access and Efficiency) in order to deliver on their vision of “Innovating Healthcare. Transforming Lives.”
Best wishes to you and yours from everyone at the Clinical Research Office/Ponce Medical School Foundation. Happy holidays and best wishes for the new year! May the joy of the holidays be with you in the upcoming year.
A benefit for Pharma & Research Community: Clinical Research Office at the Po...Dr. Roberto Torres
The CRO is a multi-disciplinary service organization supporting faculty and investigators participating in federally funded, pharma, new modalities, and investigator-initiated clinical trials.
Our mission is to strengthen PHSU clinical research by providing infrastructure, quality services, and mentorship assisting new and established investigators through every stage of the research process.
Strategically located midway between North and South America
Favorable regulatory environment
Applicability of US FDA regulations which give credibility to the conduct and validity of the trials
World class business environment
International/regional airports
Outstanding human capital
Five decades of regulatory compliance expertise
Educated, skilled, bilingual workforce
Unrivaled financial incentives*
4% or 8% fixed corporate income tax rate
Access by all mail carriers
1st Puerto Rico Patient Advocacy Group Symposium Organized by PRCCIDr. Roberto Torres
August 4, 2017. The Puerto Rico Consortium for Clinical Investigation (PRCCI) hosted the First Patient Advocacy Group Symposium in Puerto Rico on August 1st, 2017. The purpose of the event was to bring together various patient advocacy groups, patients, investigators and other individuals interested in finding innovative and joint solutions to improve the lives of Puerto Rican patients. PRCCI and their partner, Yale Center for Clinical Investigation (YCCI), introduced JUNTA for Progressive Action, Inc. (JUNTA), the oldest Latino, community-based, non-profit organization from Connecticut to the symposium. Participants learned from JUNTA about the efforts undertaken by this organization and the successes they had in community outreach for minority and underserved communities.
Research Methodology and Design Focused on Cancer ResearchDr. Roberto Torres
Programa Educativo y de Entrenamiento U-54 de UPR/MD Anderson estará ofreciendo el Curso INTD 8145: Research Methodology and Design Focused on Cancer Research este próximo semestre que inicia en agosto de 2017.
De necesitar información adicional, pueden contactarme a maria.hernandez15@upr.edu
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
2. MISSION STATEMENT
To strengthen PHSU clinical research by providing infrastructure, quality services,
and mentorship assisting new and established investigators through every stage of
the research process.
Our vision is to overcome the disparities in clinical research and treatment in
Puerto Rico by increasing the clinical research capacity and providing unique
research experiences to investigators, patients, and sponsors.
Mission
Vision
3. • Furthers the missions of PRI of ongoing research
in the basic, behavioral, public health and clinical
sciences.
• Guidance and operations
• Investigator and faculty experts
• Support to PRI scientist investigating new
therapies and new prevention options
• Access to premier medical researchers and diverse
patient populations
• Effective centralized start-up process for timely
execution
ABOUT THE CROClinical Research Office
4. Puerto Rico Clinical Trials Network
• The Moffitt Cancer Center partnership was
created to overcome the disparities in oncology
clinical research and treatment in the
Hispanic/Latino population as evidenced by
diagnosis at more advanced stages, barriers to
care, and underrepresentation in clinical cancer
trials.
• Partnership Objectives:
– Increase research capabilities
– World’s first tissue bank of Puerto Rican
tumors, and;
– Reduce health disparities in the treatment
of cancer in Hispanic patients
– Quality partner
5. Oncology Research Information Exchange Network (ORIEN)
• (ORIEN) is a unique research partnership
among North America’s top cancer centers
• Access to data is the key to cancer discovery
• Data sharing to guide discoveries
• Advancing precision-based therapy
• Founders: Moffitt Cancer, The Ohio State
University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and
Richard J. Solove Research Institute in
Columbus
• Leverage multiple data sources and match
patients to targeted treatments
RESEARCH
6. Integrated Services
• Clinical Research Office services:
– Biorepository for specimen processing and
storage
– Sponsored clinical research support
– Regulatory assistance with IRB/IACUC
submission and other compliance
measures
– Supporting faculty and investigators
participating in federally funded, pharma,
investigator-initiated clinical trials
– Point of contact to match faculty
investigators with clinical trials sponsors
7. Integrated Services
Study Development
• Feasibility
Assessments
• Grant Management
and Support
• Regulatory
Submissions (Central
or Local IRB)
• Investigator Selection
• Community
Engagement
Study Conduct
• Clinical Research Facilities
• Coordination
• Data Management
• Monitoring
• Research Pharmacy
• Regulatory Reviews
• Specimen Collection and Storage
• Sponsor Invoicing
• Staff Training
• Subject Payment Management
• Study Closeout
Study Activation
• Budget and Contract
Preparation
• Clinical Trial Team
• Regulatory and
IRB/IACUC Support
• Data Management
• Study Conduct
• Quality Assurance
• Financial
Management
• Recruitment
Planning
8. Ponce Research Institute Research Locations
CAIMED
• Ambulatory clinical
research center
(CAIMED)
• Largest clinical
research centers in
Southern Puerto Rico
• Over 300 Trials
Completed
Wellness Center
Capabilities:
• Ophthalmology
• Internal Medicine
• Family Medicine
• Rheumatology
• Mental health
• Psychiatry
• Pediatrics
• 4,000 visits a month
Hospitals
• San Lucas
• San Cristobal
• Manati Medical Center
• Mayaguez Medical Center
• Bella Vista
• Caribbean Cancer
Centers
9. Research Areas
Over 500 faculty members - experts in diverse therapeutic
areas:
• Oncology * Infectious Diseases
• Endocrinology * Drug Abuse
• Endometriosis * Gastroenterology
• Genetics * Mental Health
• Surgery * Pediatrics
• Family Medicine * Internal Medicine
• Radiology * Emergency
• Basic Science * Cardiology
• Nephrology * Neurology
13. Capacity and Reach
Ongoing projects
• Molecular epidemiology of HIV migration
• Feasibility of implementing NGS-based
genotyping
• Training and implementation of “In House”
genotyping
Educationand Training
14. Examples of studies for which our Lab has provided
support
• Detection of post-hurricane leptospirosis cases through enhanced surveillance for acute
febrile illness in southern Puerto Rico
• Dengue virus immunity in endemic and non-endemic human cohorts
• Clinical and Neurodevelopmental Outcomes of Postnatally - acquired Zika Virus
Infection among Children Aged <5 years
• Effects of Prefrontal Microglia Activation on PTSD-like Behaviors
• Targeting the Brain-Gut-Flora Axis using Probiotics in Endometriosis
• ARBO-004: Zika virus sero-prevalence and assessment of the Dual Path Platform® Zika
IgM assay to detect recent or current Zika virus infection
16. 3730 XL DNA Analyzer
• 48-capillary 3730 XL DNA Analyzer used for DNA
fragment analysis applications such as
microsatellites, AFLP, SNP analysis, mutation
detection and traditional DNA sequencing.
• In our laboratory:
– HIV-1 DR Genotyping
– HIV-1 Integrase Genotyping
– HLA SNP rs2395029 Analysis
– HCV 5’NC Genotyping
17. The MiSeq System: Next-Generation Sequencing
• Base calls are made directly from signal
intensity measurements during each cycle,
greatly reducing raw error rates compared to
other technologies.
• Microbiome Analysis
18. Flow Cytometry
• FACSCalibur: use of multiple fluorochromes
(FITC/PE/PerCP/APC) to effectively identify
and isolate subset populations in a single
sample.
19. BD FACSAria I: Cell Sorter
• Enables multicolor analysis of up
to 10 fluorescents markers and
two scatter parameters at the
same time. We have the capacity
to separate 4 subsets of cells at
the same time.
20. Luminex MAGPIX
• The Luminex MAGPIX analyzer detects up
to 50 analytes per sample and reads a 96-
well-plate in just 60 minutes. The
procedure could be performed by using as
little as 25µl of samples.
21. Mission U120 Ultra-Used to perform urinalysis of ten
parameters
• Leukocytes
• Specific Gravity
• Nitrite
• Ketone
• Urobilinogen
• Bilirubin
• Protein
• Glucose
• pH
• Blood
23. Data Core
Computer center administrated by our own network system
Used for
SPSS Statistics Use for data analysis
Nuance Power
PDF Advanced
Use for create or edit pdf documents
WM Recorder Use for recording streaming video and audio. Schedule recording for webinar,
create demonstration videos for any software program. The recorder is
available in Google Drive Storage for access by authorized personnel.
IMAC PRO
(RISE)
Use for analysis NGS Data
Work Centre
Xerox 4250
Print, Copy, Fax and Network Scan
24. GLU, UA, CHO, TG, BUN, TBIL, CA, TP ,ALB, ALT,
AST, CPK, AMY, GGT, ALP, Crea, Fructosamine,
Phosphorus, Magnesium, LDH, HDL, LDL
Panels: Lipid panel: TG, CHO, HDL
Basic Panel 1: ALB, BUN, GLU, CRE, CAL
Basic Panel 2: ALP, T-Bil, ALT, AST, T-Pro
• PBMC isolation:
isolation of cells
at the required
concentration,
cell count,
viability analysis
• Phlebotomy and
sample
processing
Other Services
25. Meet the Team
Roberto Torres, DHA
Director, Clinical Research
Office
Email: rtorres@psm.edu
Phone: 214-564-4869
Tacia M. Torres
Senior Grant Writer
Laura Domenech, MD
Senior Medical Officer
María E. Rojas, Pharm. D, MS
Senior, Clinical Research
Coordinator
Jessica Echevarria
Clinical Research Office
Operations Specialist/Regulatory
Inno Diagnostics
Dr. Vanessa Rivera Amil
Scientific Director
Glendaliz Melendez
Clinical Research Coordinator
Julia Batista
Clinical Research Coordinator
Mercedes Negron,
Clinical
Research Coordinator
Marta Villareal, PhD
Research Program Coordinator
Carmen Narvaez,
Clinical Research Coordinator